219 related articles for article (PubMed ID: 23810180)
1. New antibiotics for paediatric use: a review of a decade of regulatory trials submitted to the European Medicines Agency from 2000--why aren't we doing better?
Garazzino S; Lutsar I; Bertaina C; Tovo PA; Sharland M
Int J Antimicrob Agents; 2013 Aug; 42(2):99-118. PubMed ID: 23810180
[TBL] [Abstract][Full Text] [Related]
2. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
[TBL] [Abstract][Full Text] [Related]
3. Lack of compliance of European Public Assessment Reports to guidelines for paediatric drug development before the introduction of paediatric investigation plans.
Piana C; Kliphuis E; Della Pasqua O
Clin Trials; 2013 Apr; 10(2):269-79. PubMed ID: 23335676
[TBL] [Abstract][Full Text] [Related]
4. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
5. The development of medicines for children. Part of a series on Pediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni.
Rocchi F; Tomasi P
Pharmacol Res; 2011 Sep; 64(3):169-75. PubMed ID: 21376810
[TBL] [Abstract][Full Text] [Related]
6. Development of medicines for children in Europe: ethical implications.
Saint Raymond A; Brasseur D
Paediatr Respir Rev; 2005 Mar; 6(1):45-51. PubMed ID: 15698816
[TBL] [Abstract][Full Text] [Related]
7. [Are children getting the right drugs?].
Bratlid D
Tidsskr Nor Laegeforen; 2005 Dec; 125(23):3290-2. PubMed ID: 16327857
[TBL] [Abstract][Full Text] [Related]
8. Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study.
Hwang TJ; Tomasi PA; Bourgeois FT
PLoS Med; 2018 Mar; 15(3):e1002520. PubMed ID: 29494592
[TBL] [Abstract][Full Text] [Related]
9. Antibiotic dosing in children in Europe: can we grade the evidence from pharmacokinetic/pharmacodynamic studies - and when is enough data enough?
Barker CI; Standing JF; Turner MA; McElnay JC; Sharland M
Curr Opin Infect Dis; 2012 Jun; 25(3):235-42. PubMed ID: 22517604
[TBL] [Abstract][Full Text] [Related]
10. Paediatric Drug Development and Formulation Design-a European Perspective.
Van Riet-Nales DA; Kozarewicz P; Aylward B; de Vries R; Egberts TC; Rademaker CM; Schobben AF
AAPS PharmSciTech; 2017 Feb; 18(2):241-249. PubMed ID: 27270905
[TBL] [Abstract][Full Text] [Related]
11. Standardising neonatal and paediatric antibiotic clinical trial design and conduct: the PENTA-ID network view.
Folgori L; Lutsar I; Standing JF; Walker AS; Roilides E; Zaoutis TE; Jafri H; Giaquinto C; Turner MA; Sharland M
BMJ Open; 2019 Dec; 9(12):e032592. PubMed ID: 31892658
[TBL] [Abstract][Full Text] [Related]
12. The European Regulation on medicines for paediatric use.
Dunne J
Paediatr Respir Rev; 2007 Jun; 8(2):177-83. PubMed ID: 17574163
[TBL] [Abstract][Full Text] [Related]
13. Global shortage of neonatal and paediatric antibiotic trials: rapid review.
Thompson G; Barker CI; Folgori L; Bielicki JA; Bradley JS; Lutsar I; Sharland M
BMJ Open; 2017 Oct; 7(10):e016293. PubMed ID: 29030411
[TBL] [Abstract][Full Text] [Related]
14. Development of paediatric medicines: concepts and principles.
Rose K; Della Pasqua O
Handb Exp Pharmacol; 2011; 205():111-24. PubMed ID: 21882108
[TBL] [Abstract][Full Text] [Related]
15. Drug development: EU paediatric legislation, the European Medicines Agency and its Paediatric Committee--adolescents' melanoma as a paradigm.
Rose K; Senn S
Pharm Stat; 2014; 13(4):211-3. PubMed ID: 24903307
[TBL] [Abstract][Full Text] [Related]
16. Drug policy in Europe Research and funding in neonates: current challenges, future perspectives, new opportunities.
Jacqz-Aigrain E
Early Hum Dev; 2011 Mar; 87 Suppl 1():S27-30. PubMed ID: 21269785
[TBL] [Abstract][Full Text] [Related]
17. The review of drug applications submitted to the European Medicines Evaluation Agency: frequently raised objections, and outcome.
Pignatti F; Aronsson B; Gate N; Vamvakas S; Wade G; Moulon I; Le Courtois P
Eur J Clin Pharmacol; 2002 Dec; 58(9):573-80. PubMed ID: 12525957
[TBL] [Abstract][Full Text] [Related]
18. Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe.
Roberts SA; Allen JD; Sigal EV
Health Aff (Millwood); 2011 Jul; 30(7):1375-81. PubMed ID: 21680577
[TBL] [Abstract][Full Text] [Related]
19. Antibacterial drug development: challenges, recent developments, and future considerations.
Nambiar S; Laessig K; Toerner J; Farley J; Cox E
Clin Pharmacol Ther; 2014 Aug; 96(2):147-9. PubMed ID: 25056394
[TBL] [Abstract][Full Text] [Related]
20. The development of pharmacological treatment of obesity in children. A European regulatory perspective.
Karres J; Tomasi P; Saint Raymond A
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 May; 54(5):570-6. PubMed ID: 21547648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
